Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab + tislelizumab with intraperitoneal and systemic chemotherapy for CLDN18.2-positive gastric cancer with peritoneal metastasis
ChiCTR2500105626Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zolbetuximab and tislelizumab in gastric adenocarcinoma and gastric cancer (GC), sponsored by Ruijin Hospital. Primary endpoint: 1-year overall survival rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
zolbetuximabtislelizumab
03
Conditions
gastric adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2500105626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105626.